Abstract

Wyeth Research (formerly Wyeth-Ayerst Research) is developing the sirolimus (rapamycin) analog CCI-779 as a potential treatment for various cancers [320924]. By November 2001, phase III trials had been initiated [428972], [429576]. In October 2001, Raymond James predicted filing in 2003, with a potential launch in 2005 [426718]. In March 2002, CCI-779, was designated for fast-track development by the FDA for the treatment of renal cell …

Authors

Elit L

Journal

Current Opinion in Investigational Drugs, Vol. 3, No. 8, pp. 1249–1253

Publication Date

August 2002

ISSN

1472-4472

Associated Experts

Laurie Elit

Professor, Faculty of Health Sciences

Visit profile

Labels

Fields of Research (FoR)

32 Biomedical and Clinical Sciences 3211 Oncology and Carcinogenesis 3214 Pharmacology and pharmaceutical sciences

Medical Subject Headings (MeSH)

Animals Antibiotics, Antineoplastic Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Contraindications Humans Neoplasms Protein Synthesis Inhibitors Sirolimus